+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Product Landscape, 2021

  • ID: 5517606
  • Report
  • November 2021
  • Region: Global
  • 239 Pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • 20/20 GeneSystems Inc
  • Babson Diagnostics Inc
  • DIALAB GmbH
  • Halberd Corp
  • Monopar Therapeutics Inc
  • Qlife Holding AB
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Product Landscape, 2021

Summary


the publisher's Medical Devices sector report, “COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Product Landscape, 2021' provides comprehensive information about the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

COVID 19 EIA/ELISA are the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope


– Extensive coverage of the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) under development
– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
– The report reviews the major players involved in the development of COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) and list all their pipeline projects
– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
– The report provides key clinical trial data of ongoing trials specific to pipeline products
– Recent developments in the segment / industry

Reasons to Buy


The report enables you to -
– Formulate significant competitor information, analysis, and insights to improve R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
– Identify and understand important and diverse types of COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) under development
– Develop market-entry and market expansion strategies
– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
– In-depth analysis of the product’s current stage of development, territory and estimated launch date
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 20/20 GeneSystems Inc
  • Babson Diagnostics Inc
  • DIALAB GmbH
  • Halberd Corp
  • Monopar Therapeutics Inc
  • Qlife Holding AB
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Overview

3 Products under Development
3.1 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Stage of Development
3.2 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Territory
3.3 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Regulatory Path
3.4 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Estimated Approval Date
3.5 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Ongoing Clinical Trials

4 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products under Development by Companies
4.1 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Companies - Pipeline Products by Stage of Development
4.2 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Stage of Development

5 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Companies and Product Overview

6 Appendix
6.1 Methodology
6.2 About The Publisher
6.3 Contact Us
6.4 Disclaimer

List of Tables
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Stage of Development
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Territory
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Regulatory Path
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Estimated Approval Date
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Ongoing Clinical Trials
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Companies - Pipeline Products by Stage of Development
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Stage of Development
  • Glossary

List of Figures
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Stage of Development
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Territory
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Regulatory Path
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Pipeline Products by Estimated Approval Date
  • COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Ongoing Clinical Trials
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • 20/20 GeneSystems Inc
  • Abbott Diagnostics
  • Abbott Laboratories
  • Absology Co Ltd
  • Abwiz Bio Inc
  • Achira Labs Pvt Ltd
  • ADiTx Therapeutics Inc
  • ADMA Biologics Inc
  • AegirBio AB
  • Aegis Sciences Corp
  • Affigenix Biosolutions Pvt Ltd
  • Agilent Technologies Inc
  • ALPCO Diagnostics
  • Anhui Deep Blue Medical Technology Co Ltd
  • Ansh Labs LLC
  • Arrayit Corp
  • ARUP Laboratories
  • Avacta Group Plc
  • Axim Biotechnologies Inc
  • Axium BioResearch Inc
  • Babson Diagnostics Inc
  • Base10 Genetics Inc
  • Beckman Coulter Inc
  • Beijing Shengkun Kangru Medical Equipment Co Ltd
  • Ben-Gurion University of the Negev
  • Biohit Healthcare Ltd
  • BioIQ Inc
  • Biolinker Synthetic Biology Ltd
  • Biomerica Inc
  • Bio-Techne Corp
  • BioVaxys Technology Corp
  • Bloom Diagnostics AG
  • Boston University
  • BreviTest Technologies LLC
  • Calviri Inc
  • Capricor Therapeutics Inc
  • CareHealth America Corp
  • Cellex Inc
  • Cellmid Ltd
  • Celltrion Inc
  • Core Technology Co Ltd
  • DiaCarta Inc
  • Diagnostics Biochem Canada Inc
  • DIALAB GmbH
  • DiaSorin SpA
  • Diazyme Laboratories Inc
  • DLS Research and Ventures
  • DRG International Inc
  • EDP Biotech Corporation
  • Empower Clinics Inc
  • Enable Biosciences Inc
  • Enzo Biochem Inc
  • Epigentek Group Inc
  • Epitope Diagnostics, Inc.
  • Eurobio Scientific SA
  • Eurofins Scientific SE
  • Euroimmun AG
  • Excelsior Bio-Systems Inc
  • Ezra AI Inc
  • Fujirebio Diagnostics Inc
  • General Biologicals Corp
  • Halberd Corp
  • Hecin Scientific Inc
  • Hunan Lituo Biotechnology Co Ltd
  • Icosagen AS
  • ICT International
  • IDvet
  • Immunodiagnostics Ltd
  • ImmunoPrecise Antibodies Ltd
  • Indian Institute of Technology Guwahati
  • Interpace Biosciences Inc
  • Kantaro Biosciences LLC
  • Kephera Diagnostics LLC
  • KRISHGEN BioSystems
  • Lansion Biotechnology Co Ltd
  • Leadgene Biomedical Inc
  • Leinco Technologies Inc
  • Liquid Diagnostics LLC
  • Lumos Diagnostics Inc
  • Maxim Biomedical Inc
  • Meridian Bioscience Inc
  • Module Innovations Pvt Ltd
  • Mologic Ltd
  • Monarch Global Health LLC
  • Monopar Therapeutics Inc
  • Nanjing Liming Bio-Products Co Ltd
  • NanoRepro AG
  • Nirmidas Biotech Inc
  • Northwestern University
  • Novacyt SA
  • NovaTec Immundiagnostica GmbH
  • Novo Nordisk AS
  • OraSure Technologies Inc
  • Ortho Clinical Diagnostics Holdings Plc
  • Oy Medix Biochemica Ab
  • P3 Diagnostics LLC
  • Pepex Biomedical, Inc.
  • PerkinElmer Inc
  • Pinnacle BioLabs
  • Prantae Solutions Pvt Ltd
  • Premier Medical Corporation
  • ProAxsis Ltd
  • ProGnosis Biotech SA
  • Promega Corp
  • ProMIS Neurosciences Inc
  • Qiagen NV
  • Qlife Holding AB
  • Quanterix Corp
  • Quotient Ltd
  • Randox Laboratories Ltd
  • Roche Diagnostics International Ltd
  • Safetest Comercio de Diagnosticos Ltd
  • Salofa Oy
  • ScheBo Biotech AG
  • Sciteck Diagnostics Inc
  • Shenzhen Kingfocus Biomedical Engineering Co Ltd
  • Shenzhen Tisenc Medical Devices Co Ltd
  • Shijiazhuang Hipro Biotechnology Co Ltd
  • Siemens Healthcare Diagnostics Inc
  • Siemens Healthineers AG
  • SQI Diagnostics Inc
  • St Petersburg Research Institute of Vaccines and Serums
  • Stream Bio Ltd
  • Syngene
  • Sysmex Corp
  • Taizhou ZECEN Biotech Co Ltd
  • The Binding Site Inc
  • ThermoGenesis Holdings Inc
  • Trinity College Dublin
  • University of Melbourne
  • VidaCheck LLC
  • VirIntel LLC
  • Vivera Pharmaceuticals Inc
  • Vyriad Inc
  • West Virginia University School of Medicine
  • Zalgen Labs LLC
  • Zandcell AB
  • ZRT Laboratory LLC
Note: Product cover images may vary from those shown